Candel Therapeutics Q3 2023 net loss $8.4M; cash runway into Q2 2024

Candel Therapeutics, Inc.

2023-Q3 EPS reported -$0.93

Net loss of $8.4M in Q3 2023, versus $8.7M loss in Q3 2022; no revenue recognized.
Cash and equivalents $43.0M as of Sept 30, 2023; expected to fund operations into Q2 2024.
R&D expenses $5.8M (+7.4% YoY) driven by CAN-2409 manufacturing and regulatory work.
G&A expenses $3.0M (-14.3% YoY) due to lower professional service and consulting costs.
Topline overall survival data for CAN-2409 in NSCLC expected Q2 2024; prostate cancer data in Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Candel Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061558

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.